ALYSON FERGUSON: Open Payments
NPI 1952971822 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,129 in 133 payments from 23 companies in 2025. Trend: 2023 $1,723 · 2024 $1,619 · 2025 $2,129
Food & beverage: $2,129
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $405 |
| PFIZER INC. | 17 | $265 |
| Novo Nordisk Inc | 15 | $256 |
| Otsuka America Pharmaceutical, Inc. | 17 | $199 |
| AstraZeneca Pharmaceuticals LP | 5 | $177 |
| Axsome Therapeutics, Inc. | 11 | $166 |
| Amgen Inc. | 16 | $157 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $92 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $55 |
| Merck Sharp & Dohme LLC | 2 | $39 |
Products named: VRAYLAR, REXULTI, Wegovy, NURTEC ODT, OTEZLA, QULIPTA, BREZTRI, XIFAXAN.
Industry payments across NE — which companies pay providers there.
